急性脑梗死加用依达拉奉治疗的疗效观察

Efficacy of edaravone in treatment of patients with acute cerebral infarction

目的探讨常规治疗急性脑梗死和加用依达拉奉治疗急性脑梗死的疗效变化。方法70例急性脑梗死患者随机分为治疗组和对照组,每组各35例,对照组用常规治疗方法(丹参或参麦和胞二磷胆碱静滴,口服阿司匹林等治疗),治疗组在常规治疗的基础上加用依达拉奉注射液30 mg,静脉滴注,每天2次,7～14 d为1个疗程,3天后进行疗效评定。结果1周后治疗组、对照组ESS评分分别为70.38±16.32、64.40±14.45,3周后治疗组、对照组ESS评分分别为82.40±13.8、76.90±13.8,两组对比差异均有显著性,前者P<0.05,后者P<0.01。而从治疗组和对照组的起效时间相比,治疗组明显早于对照组,差异有显著性。结论依达拉奉注射液30 mg静脉滴注,每日2次治疗,能有效改善急性脑梗死的神经功能缺失和日常生活能力,并能更好地控制脑梗死的进展。

Objective To explore the efficacy and adverse reactions of treatment of acute cerebral infarction （ACI） by edaravone. Methods A randomized controlled study was carried out in treatment of 70 patients with ACI. They were randomly divided into treatment group （ n = 35 ） and control group （ n = 35 ）. Patients in both groups were given Dansh- en or Shenmai injection and aspirin orally once per day. Patients in treatment group received edaravone injection 30mg twice per day for 7 - 14 days as well. The neurological deficits of patients in both groups were assessed by Europe Stroke Scale （ESS） three days after treatment. Clinical efficacy was evaluated according to changes of ESS scores on the 7th and 21th day. Results The efficacy rates in treatment group and control group were 70.38 ± 16.32 and 64.4 ± 14.45 respectively （P 〈 0.05 ） on the 7th day, 82.4 ± 13.8,76.9 ± 13.8 respectively （P 〈 0.01 ） on the 21 th day. There was a significant difference in ESS scores between treatment group and control group（ P 〈0.05 ）. There was also a signifi- cant difference in onset time in these two groups. Conclusions Edaravone can improve impaired neurological function and activities of daily living in patients with acute cerebral infarction without obviously adverse reaction. Edaravone is effective and safe in treatment of patients with acute cerebral infarction. It is worthy of being recommended for clinical application.